Inotropic agents improve the peripheral microcirculation of patients with end-stage chronic heart failure

J Card Fail. 2008 Jun;14(5):400-6. doi: 10.1016/j.cardfail.2008.02.001.

Abstract

Background: Skeletal muscle microcirculation impairment in patients with chronic heart failure (CHF) seems to correlate with disease severity. We evaluated the microcirculation by near-infrared spectroscopy (NIRS) occlusion technique before and after inotropic infusion.

Methods: We evaluated 25 patients with stable CHF, 30 patients with end-stage CHF (ESCHF) receiving treatment with intermittent infusion of inotropic agents, and 12 healthy subjects. Thenar muscle tissue oxygen saturation (StO(2)%) was measured noninvasively by NIRS before, during, and after 3-minute occlusion of the brachial artery (occlusion technique) in all subjects and in patients with ESCHF before and after 6 hours of inotropic infusion (dobutamine and/or levosimendan) or placebo (N = 5).

Results: Patients with ESCHF or CHF presented significantly lower StO(2)% than healthy subjects (74.5% +/- 7%, 78.6% +/- 6%, and 85% +/- 5%, respectively; P = .0001), lower oxygen consumption rate during occlusion (24.6% +/- 8%/min, 28.6% +/- 10%/min, and 38.1% +/- 11.1%/min, respectively; P = .001), and lower reperfusion rate (327% +/- 141%/min, 410% +/- 106%/min, and 480% +/- 133%/min, respectively; P = .002). After 6 hours of inotropic infusion, patients with ESCHF showed significantly increased StO(2)% (74.5% +/- 7% to 82% +/- 9%, P = .001), oxygen consumption rate (24.6% +/- 8%/min to 29.3% +/- 8%/min, P = .009), and reperfusion rate (327% +/- 141%/min to 467% +/- 151%/min, P = .001). No statistical difference was noted in the placebo group.

Conclusion: Peripheral muscle microcirculation as assessed by NIRS is impaired in patients with CHF. This impairment is partially reversed by infusion of inotropic agents in patients with ESCHF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / therapeutic use
  • Brachial Artery
  • Cardiotonic Agents / therapeutic use*
  • Case-Control Studies
  • Chronic Disease
  • Dobutamine / therapeutic use
  • Female
  • Heart Failure / diagnosis
  • Heart Failure / drug therapy*
  • Humans
  • Hydrazones / therapeutic use
  • Male
  • Microcirculation / drug effects
  • Middle Aged
  • Muscle, Skeletal / blood supply*
  • Myocardial Reperfusion
  • Oxygen Consumption
  • Prognosis
  • Prospective Studies
  • Pyridazines / therapeutic use
  • Simendan
  • Spectroscopy, Near-Infrared
  • Vasodilator Agents / therapeutic use

Substances

  • Adrenergic beta-Agonists
  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Vasodilator Agents
  • Simendan
  • Dobutamine